Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions
Year: 2004
Type: article
Study design: Clinical Trial
Source: Blood
Institutions: Johns Hopkins University, The Ohio State University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: National Cancer Institute
OpenAlex ID: W2159880472
